Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | GLI1 | P08151 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Proline SCHEMBL15210884 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL20897288 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| D-Proline SCHEMBL5665276 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL19947289 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL3442547 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL3428913 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL499448 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL28093320 | 0.96 | NOS2 (0.40) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL28101824 | 0.96 | NOS2 (0.40) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL1828861 | 0.95 | NOS2 (0.39) | NOS2NOS3NOS1MEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559733-B2 | Optimization of type IV BRAF inhibitors for the treatment of melanoma | UNIVERSITY OF SOUTH CAROLINA (US) | 2026-02-24 | — | — | US | claimed |
| EP-4695274-A1 | MODULAR RE-TARGETING OF RHABDOVIRAL (G) GLYCOPROTEINS FROM THEIR NATURAL RECEPTORS | Vyriad (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4695273-A1 | CD3-REDIRECTED VECTORS, COMPONENTS THEREOF, AND USES OF THE VECTORS AND COMPONENTS THEREOF | Vyriad (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250353883-A1 | NOVEL RECOMBINANT AAV VP2 FUSION POLYPEPTIDES | NOVARTIS AG (CH) | 2025-11-20 | — | — | US | claimed |
| US-12472232-B2 | Methods to treat viral infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-11-18 | — | — | US | claimed |
| US-20250345420-A1 | CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION | UNIV CORNELL (US) | 2025-11-13 | — | — | US | claimed |
| WO-2025217533-A2 | RECOMBINANT RHABDOVIRAL G GLYCOPROTEINS AND USES THEREOF | VYRIAD (US) | 2025-10-16 | — | — | WO | claimed |
| US-12317911-B2 | Flavor compositions and screening methods for identifying the same | MARS, INCORPORATED (US) | 2025-06-03 | — | — | US | claimed |
| CN-120064628-A | Metabolic marker for evaluating operation prognosis of hypertrophic cardiomyopathy patient and application | 中国医学科学院阜外医院 | 2025-05-30 | — | — | CN | claimed |
| WO-2025108375-A1 | CONSTRUCT FOR PROTEIN DEGRADATION AND USE THEREOF | 深圳湾实验室 | 2025-05-30 | — | — | WO | claimed |
| WO-2010065876-A2 | METHODS AND COMPOSITIONS RELATED TO TH-1 DENDRITIC CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | WO | claimed |
| US-20100015070-A1 | USE OF NATURAL, RECOMBINANT AND SYNTHETIC RESILINS IN COSMETICS | BASF SE (DE) | 2010-01-21 | — | — | US | claimed |
| CN-101563104-A | Polypeptide-nucleic acid conjugates for immunoprophylaxis or immunotherapy of neoplastic or infectious diseases | UNIV JOHNS HOPKINS (US) | 2009-10-21 | — | — | CN | claimed |
| CN-101390600-A | Preparation method of seafresh flavor essence | TIANJIN SHUANGXING ESSENCE & S (CN) | 2009-03-25 | — | — | CN | claimed |
| EP-1986698-A2 | POLYPEPTIDE-NUCLEIC ACID CONJUGATE FOR IMMUNOPROPHYLAXIS OR IMMUNOTHERAPY FOR NEOPLASTIC OR INFECTIOUS DISORDERS | The Johns Hopkins University (US) | 2008-11-05 | — | — | EP | claimed |
| US-20070212337-A1 | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-09-13 | — | — | US | claimed |
| WO-2007089871-A2 | POLYPEPTIDE-NUCLEIC ACID CONJUGATE FOR IMMUNOPROPHYLAXIS OR IMMUNOTHERAPY FOR NEOPLASTIC OR INFECTIOUS DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-09 | — | — | WO | claimed |
| US-20050147621-A1 | Use of bacterial 5' untranslated regions for nucleic acid expression | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2005-07-07 | — | — | US | claimed |
| US-20040057958-A1 | Immunogenicity-enhancing carriers and compositions thereof and methods of using the same | CELL THERAPEUTICS, INC. | 2004-03-25 | — | — | US | claimed |
| CN-87106235-A | Treat atherosclerotic method and base composition | — | 1988-05-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559733-B2 | Optimization of type IV BRAF inhibitors for the treatment of melanoma | BRAF, RAF1, ARAF | NOS2 3781/4885NOS3 4267/4885NOS1 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.